Medication Class | Switch (N = 153) | |
---|---|---|
Patients | Treatment Duration (months) | |
Any prior preventive therapy | 153 (100%) | N.A |
Beta-blockers | 132 (86.3%) | 13.5 ± 23.3 |
Calcium Channel Blockers | 88 (57.5%) | 4.5 ± 7.1 |
Anticonvulsants | 144 (94.1%) | 9.4 ± 16.2 |
Antidepressants | 141 (92.2%) | 10.6 ± 17.6 |
Onabotulinumtoxin A | 83 (54.2%) | 10.6 ± 14.2 |
Any anti-CGRP pathway mAb | 153 (100%) | N.A |
Erenumab 70 mg | 93 (60.8%) | 6.4 ± 6.7 |
Erenumab 140 mg | 110 (71.9%) | 8.5 ± 7.1 |
Any erenumab | 145 (94.8%) | 10.6 ± 8.8 |
Galcanezumab | 16 (10.5%) | 7.4 ± 3.6 |